Half-year report · Q2
4885.TEDINET S100V2K6
Period2024-06-01 → 2024-11-30
Filed2025-01-14
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥3.0bn | 2024-06-01 → 2024-11-30 | Standalone | Net sales |
| Revenue | ¥6.4bn | 2023-06-01 → 2024-05-31 | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.9bn | 2023-06-01 → 2023-11-30 | Standalone | Net sales |
| Operating income | ¥154m | 2024-06-01 → 2024-11-30 | Standalone | Operating income |
| Operating income | ¥115m | 2023-06-01 → 2023-11-30 | Standalone | Operating income |
| Ordinary income | ¥171m | 2024-06-01 → 2024-11-30 | Standalone | Ordinary income |
| Ordinary income | ¥428m | 2023-06-01 → 2024-05-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥110m | 2023-06-01 → 2023-11-30 | Standalone | Ordinary income |
| Profit before tax | ¥171m | 2024-06-01 → 2024-11-30 | Standalone | Income before income taxes |
| Profit before tax | ¥145m | 2023-06-01 → 2023-11-30 | Standalone | Income before income taxes |
| Net income | ¥121m | 2024-06-01 → 2024-11-30 | Standalone | Profit loss |
| Net income | ¥330m | 2023-06-01 → 2024-05-31 | Standalone | Net income loss (5-year summary) |
| Net income | ¥93m | 2023-06-01 → 2023-11-30 | Standalone | Profit loss |
| Total assets | ¥5.5bn | at 2024-11-30 | Standalone | Assets |
| Total assets | ¥5.1bn | at 2024-05-31 | Standalone | Assets |
| Total assets | ¥5.1bn | at 2023-11-30 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥3.2bn | at 2024-11-30 | Standalone | Liabilities |
| Total liabilities | ¥2.8bn | at 2024-05-31 | Standalone | Liabilities |
| Net assets / equity | ¥2.3bn | at 2024-11-30 | Standalone | Net assets |
| Net assets / equity | ¥2.3bn | at 2024-05-31 | Standalone | Net assets |
| Net assets / equity | ¥2.0bn | at 2023-11-30 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.3bn | at 2024-11-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.1bn | at 2024-05-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.3bn | at 2024-11-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2024-05-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2023-11-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥853m | at 2023-05-31d | Standalone | Cash and cash equivalents |
| Operating cash flow | ¥137m | 2024-06-01 → 2024-11-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | ¥638m | 2023-06-01 → 2024-05-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥143m | 2023-06-01 → 2023-11-30 | Standalone | Net cash provided by used in operating activities |
| Investing cash flow | −¥188m | 2024-06-01 → 2024-11-30 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥232m | 2023-06-01 → 2024-05-31 | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥115m | 2023-06-01 → 2023-11-30 | Standalone | Net cash provided by used in investment activities |
| Financing cash flow | ¥336m | 2024-06-01 → 2024-11-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | −¥210m | 2023-06-01 → 2024-05-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥185m | 2023-06-01 → 2023-11-30 | Standalone | Net cash provided by used in financing activities |
| EPS (basic) | ¥30.29 | 2024-06-01 → 2024-11-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥83.42 | 2023-06-01 → 2024-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.63 | 2023-06-01 → 2023-11-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥29.82 | 2024-06-01 → 2024-11-30 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥81.86 | 2023-06-01 → 2024-05-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥23.16 | 2023-06-01 → 2023-11-30 | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥22 | 2023-06-01 → 2024-05-31 | Standalone | Dividend paid per share (5-year summary) |
| Equity ratio | 42.2% | at 2024-11-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.9% | at 2024-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.9% | at 2023-11-30 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 4,095,500 | at 2024-11-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,095,500 | at 2024-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,095,500 | at 2023-11-30 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 24
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E36350-000Chemical Products Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥1.1bn |
| jpcrp040300-q2r_E36350-000Chemical Products Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥1.1bn |
| jpcrp040300-q2r_E36350-000Chemical Products Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | −¥17m |
| jpcrp040300-q2r_E36350-000Healthy Food Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥523m |
| jpcrp040300-q2r_E36350-000Healthy Food Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥523m |
| jpcrp040300-q2r_E36350-000Healthy Food Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥5m |
| jpcrp040300-q2r_E36350-000Pharmaceutical Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥1.4bn |
| jpcrp040300-q2r_E36350-000Pharmaceutical Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥1.4bn |
| jpcrp040300-q2r_E36350-000Pharmaceutical Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥167m |
| —segment total | revenue | 2024-06-01 → 2024-11-30 | ¥3.0bn |
| —segment total | revenue external | 2024-06-01 → 2024-11-30 | ¥3.0bn |
| —segment total | segment profit | 2024-06-01 → 2024-11-30 | ¥154m |
| jpcrp040300-q2r_E36350-000Chemical Products Businessreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥1.0bn |
| jpcrp040300-q2r_E36350-000Chemical Products Businessreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥1.0bn |
| jpcrp040300-q2r_E36350-000Chemical Products Businessreportable segment | segment profit | 2023-06-01 → 2023-11-30 | −¥55m |
| jpcrp040300-q2r_E36350-000Healthy Food Businessreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥379m |
| jpcrp040300-q2r_E36350-000Healthy Food Businessreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥379m |
| jpcrp040300-q2r_E36350-000Healthy Food Businessreportable segment | segment profit | 2023-06-01 → 2023-11-30 | −¥28m |
| jpcrp040300-q2r_E36350-000Pharmaceutical Businessreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥1.5bn |
| jpcrp040300-q2r_E36350-000Pharmaceutical Businessreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥1.5bn |
| jpcrp040300-q2r_E36350-000Pharmaceutical Businessreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥198m |
| —segment total | revenue | 2023-06-01 → 2023-11-30 | ¥2.9bn |
| —segment total | revenue external | 2023-06-01 → 2023-11-30 | ¥2.9bn |
| —segment total | segment profit | 2023-06-01 → 2023-11-30 | ¥115m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 506
| Item | Context | Value | Unit |
|---|---|---|---|
| Electronically recorded monetary claim assignment | CurrentQuarterDuration_NonConsolidatedMember | 41439000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E36350-000PharmaceuticalBusinessReportableSegmentMember | 1525130000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E36350-000HealthyFoodBusinessReportableSegmentMember | 378840000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E36350-000ChemicalProductsBusinessReportableSegmentMember | 1008354000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember | 2912325000 | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration_NonConsolidatedMember | 2912325000 | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E36350-000PharmaceuticalBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E36350-000HealthyFoodBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E36350-000ChemicalProductsBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_NonConsolidatedMember | － | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E36350-000PharmaceuticalBusinessReportableSegmentMember | 1525130000 | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E36350-000HealthyFoodBusinessReportableSegmentMember | 378840000 | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E36350-000ChemicalProductsBusinessReportableSegmentMember | 1008354000 | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember | 2912325000 | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration_NonConsolidatedMember | 2912325000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E36350-000PharmaceuticalBusinessReportableSegmentMember | 198488000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E36350-000HealthyFoodBusinessReportableSegmentMember | -27920000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E36350-000ChemicalProductsBusinessReportableSegmentMember | -55251000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_ReportableSegmentsMember | 115315000 | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1YTDDuration_NonConsolidatedMember | 115315000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E36350-000PharmaceuticalBusinessReportableSegmentMember | 1352258000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E36350-000HealthyFoodBusinessReportableSegmentMember | 523451000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E36350-000ChemicalProductsBusinessReportableSegmentMember | 1089319000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember | 2965030000 | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration_NonConsolidatedMember | 2965030000 | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E36350-000PharmaceuticalBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E36350-000HealthyFoodBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E36350-000ChemicalProductsBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_NonConsolidatedMember | － | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E36350-000PharmaceuticalBusinessReportableSegmentMember | 1352258000 | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E36350-000HealthyFoodBusinessReportableSegmentMember | 523451000 | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E36350-000ChemicalProductsBusinessReportableSegmentMember | 1089319000 | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember | 2965030000 | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Net sales | CurrentYTDDuration_NonConsolidatedMember | 2965030000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E36350-000PharmaceuticalBusinessReportableSegmentMember | 166642000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E36350-000HealthyFoodBusinessReportableSegmentMember | 5021000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E36350-000ChemicalProductsBusinessReportableSegmentMember | -17178000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_ReportableSegmentsMember | 154486000 | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Operating income | CurrentYTDDuration_NonConsolidatedMember | 154486000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |